Back to Search
Start Over
Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals
- Source :
- Human Gene Therapy; September 2005, Vol. 16 Issue: 9 p1065-1074, 10p
- Publication Year :
- 2005
-
Abstract
- The present study examined the safety and relative in vivo survival of genetically engineered CD4+ T lymphocytes in human immunodeficiency virus (HIV)-infected individuals. Ten pairs of identical twins discordant for HIV infection were recruited, with the uninfected twin serving as the lymphocyte donor. Ten subjects were treated with a total of 19 separate infusions of retroviral vector-transduced CD4+ enriched T cells. Control (neo gene) or anti-HIV gene (antisense trans-activation response [TAR] element and/or trans-dominant Rev)-engineered lymphocytes were monitored in peripheral blood for 3 years, using a vector-specific PCR assay. Data from 9 of the 10 patients (15 of the 19 infusions) demonstrated preferential survival of CD4+ lymphocytes containing the anti-HIV gene(s) in the immediate weeks after infusion. In six of six patients studied long term (>100 weeks), only T cells containing the anti-HIV genes were consistently detected. In addition, a marked survival advantage of anti-HIV gene-containing T cells was observed in a patient treated during a period of high viral load. Thus, these data strongly support the hypothesis that anti-HIV genes afford a survival advantage to T cells and potential benefit to HIV-1+ individuals.
Details
- Language :
- English
- ISSN :
- 10430342 and 15577422
- Volume :
- 16
- Issue :
- 9
- Database :
- Supplemental Index
- Journal :
- Human Gene Therapy
- Publication Type :
- Periodical
- Accession number :
- ejs7624649
- Full Text :
- https://doi.org/10.1089/hum.2005.16.1065